Yiwey Shieh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yiwey Shieh has a total of 308 co-authors. Here are the top co-authors by number of shared publications:
- Eunji Choi
Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, USA
18 shared publications - Anil Vachani
University of Pennsylvania, Philadelphia, PA
16 shared publications - Julie A. Barta
Division of Pulmonary and Critical Care Medicine, Jane and Leonard Korman Respiratory Institute, Thomas Jefferson University, Philadelphia, PA
16 shared publications - Rulla M. Tamimi
Department of Population Health Sciences, Weill Cornell Medicine, New York, USA
16 shared publications - Christine Ann Garcia
Division of Hematology and Oncology, Department of Medicine Weill Cornell Medicine New York New York USA
15 shared publications - Evan Sholle
Weill Cornell Medicine, New York Presbyterian Hospital , New York, NY 10065
15 shared publications
Latest Publications
- 23 June 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (10) , 1942-1952
Comparative 10-year performance of mammography artificial intelligence, polygenic, and clinical breast cancer risk models in the Kaiser Permanente Research Bank
Background: We compared performance across 3 breast cancer risk domains—clinical, polygenic, and mammography artificial intelligence—alone and in combination over a 10-year time horizon among women with a negative screening mammogram within a Kaiser Permanente Research Bank (KPRB) prospective cohort. Methods: The study included 82 957 women (61 962 non-Hispanic White, 7256 Asian, 3414 Black, and 5466 Latina) who enrolled in KPRB between 2003 to 2020. Women with a prior history of breast cancer or high/moderate-penetrant gene mutation were excluded. The negative screening mammogram (no clinically visible cancer) closest to enrollment was used to generate the Mirai mammography AI risk score. KPRB survey and electronic health record data were used to generate the Breast Cancer Surveillance Consortium version 3 (BCSCv3) clinical risk score. Genome-wide genotypes were used to compute the 313-SNP polygenic risk score, adjusted for genetic ancestry (PRS313adj). Risks of breast cancer (invasive or ductal carcinoma in situ) at 0 to 10 years after the mammogram were estimated using Cox models, with 5-fold cross-validation used to estimate the C-index. Results: During 10 years of follow-up, 2471 women developed breast cancer. The C-index (95% CI) for the combined model with all 3 risk scores (0.70; 95% CI = 0.69 to 0.71) was significantly higher than for univariate models with only the BCSCv3 (0.62; 95% CI = 0.61 to 0.63), PRS313adj (0.61; 95% CI = 0.60 to 0.62), or Mirai (0.66; 95% CI = 0.65 to 0.67) risk score. Conclusions: Integrating mammographic AI and polygenic risk scores with clinical risk models significantly improved breast cancer risk discrimination, supporting use of combined models for personalized screening and prevention.
- 23 June 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (10) , 1942-1952
Comparative 10-year performance of mammography artificial intelligence, polygenic, and clinical breast cancer risk models in the Kaiser Permanente Research Bank
Background: We compared performance across 3 breast cancer risk domains—clinical, polygenic, and mammography artificial intelligence—alone and in combination over a 10-year time horizon among women with a negative screening mammogram within a Kaiser Permanente Research Bank (KPRB) prospective cohort. Methods: The study included 82 957 women (61 962 non-Hispanic White, 7256 Asian, 3414 Black, and 5466 Latina) who enrolled in KPRB between 2003 to 2020. Women with a prior history of breast cancer or high/moderate-penetrant gene mutation were excluded. The negative screening mammogram (no clinically visible cancer) closest to enrollment was used to generate the Mirai mammography AI risk score. KPRB survey and electronic health record data were used to generate the Breast Cancer Surveillance Consortium version 3 (BCSCv3) clinical risk score. Genome-wide genotypes were used to compute the 313-SNP polygenic risk score, adjusted for genetic ancestry (PRS313adj). Risks of breast cancer (invasive or ductal carcinoma in situ) at 0 to 10 years after the mammogram were estimated using Cox models, with 5-fold cross-validation used to estimate the C-index. Results: During 10 years of follow-up, 2471 women developed breast cancer. The C-index (95% CI) for the combined model with all 3 risk scores (0.70; 95% CI = 0.69 to 0.71) was significantly higher than for univariate models with only the BCSCv3 (0.62; 95% CI = 0.61 to 0.63), PRS313adj (0.61; 95% CI = 0.60 to 0.62), or Mirai (0.66; 95% CI = 0.65 to 0.67) risk score. Conclusions: Integrating mammographic AI and polygenic risk scores with clinical risk models significantly improved breast cancer risk discrimination, supporting use of combined models for personalized screening and prevention.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Method 1 from Design and Creation of a Racially Diverse Lung Cancer Registry with Detailed Genomic and Environmental Annotation
Supplementary Method 1. Final version of the EGFR NLP prompt.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Method 1 from Design and Creation of a Racially Diverse Lung Cancer Registry with Detailed Genomic and Environmental Annotation
Supplementary Method 1. Final version of the EGFR NLP prompt.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Design and Creation of a Racially Diverse Lung Cancer Registry with Detailed Genomic and Environmental Annotation
Supplementary Table 5. Natural language processing (NLP) Model Performance for Smoking Status Classification in Training and Testing Datasets, Stratified by Subgroup.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Design and Creation of a Racially Diverse Lung Cancer Registry with Detailed Genomic and Environmental Annotation
Supplementary Table 5. Natural language processing (NLP) Model Performance for Smoking Status Classification in Training and Testing Datasets, Stratified by Subgroup.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Design and Creation of a Racially Diverse Lung Cancer Registry with Detailed Genomic and Environmental Annotation
Supplementary Table 1. Personnel and effort involved in establishing MCC-MELD.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Design and Creation of a Racially Diverse Lung Cancer Registry with Detailed Genomic and Environmental Annotation
Supplementary Table 1. Personnel and effort involved in establishing MCC-MELD.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Design and Creation of a Racially Diverse Lung Cancer Registry with Detailed Genomic and Environmental Annotation
Supplementary Figure 2. Note selection for smoking NLP model development and annotators’ agreement.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Design and Creation of a Racially Diverse Lung Cancer Registry with Detailed Genomic and Environmental Annotation
Supplementary Figure 2. Note selection for smoking NLP model development and annotators’ agreement.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Design and Creation of a Racially Diverse Lung Cancer Registry with Detailed Genomic and Environmental Annotation
Supplementary Table 3. Distribution of development and test sets by smoking natural language processing (NLP) by calendar year.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Design and Creation of a Racially Diverse Lung Cancer Registry with Detailed Genomic and Environmental Annotation
Supplementary Table 3. Distribution of development and test sets by smoking natural language processing (NLP) by calendar year.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from Design and Creation of a Racially Diverse Lung Cancer Registry with Detailed Genomic and Environmental Annotation
Supplementary Materials and Methods: Proposal
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from Design and Creation of a Racially Diverse Lung Cancer Registry with Detailed Genomic and Environmental Annotation
Supplementary Materials and Methods: Proposal
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Design and Creation of a Racially Diverse Lung Cancer Registry with Detailed Genomic and Environmental Annotation
Background:The proportion of lung cancers affecting individuals who have never smoked is growing, with these cancers being prone to harbor mutations in the EGFR gene. Little is known about risk factors and prognostic indicators for EGFR-mutant cancers, with current research limited by the scarcity of datasets integrating genomic, clinical, and environmental data.Methods:We created the Meyer Cancer Center Molecularly Enhanced Lung Cancer Database (MCC-MELD), including lung cancer cases from a large catchment area in New York City. We identified cases through linkage to our institution’s cancer registry and a clinician-initiated, manually curated database. We linked all cases to the electronic health record and in-house tumor genomic testing results. We used natural language processing (NLP) to extract unstructured genomic testing results and detailed smoking history. We linked geocoded addresses to detailed area-level measures.Results:MCC-MELD contains 9,573 patients with lung cancer diagnosed from 1988 to 2024, of whom 20% were non-Hispanic Asian, 14% were non-Hispanic Black, and 8% were Hispanic. We identified 1,092 (11.4%) EGFR-mutant cancers, with NLP identifying 397 cases not identified by structured data. NLP showed high accuracy in ascertaining EGFR status (97%) and quantitative smoking history variables (90%–98%). Never smokers made up 16% of the cases in MCC-MELD.Conclusions:MCC-MELD is an NLP-enhanced database containing clinical information, genomic testing results, and linkages to area-level data for patients with lung cancer from a diverse urban setting.Impact:This resource can facilitate studies on lung cancer risk factors, treatment patterns, and outcomes by EGFR and other driver mutation status.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Design and Creation of a Racially Diverse Lung Cancer Registry with Detailed Genomic and Environmental Annotation
Background:The proportion of lung cancers affecting individuals who have never smoked is growing, with these cancers being prone to harbor mutations in the EGFR gene. Little is known about risk factors and prognostic indicators for EGFR-mutant cancers, with current research limited by the scarcity of datasets integrating genomic, clinical, and environmental data.Methods:We created the Meyer Cancer Center Molecularly Enhanced Lung Cancer Database (MCC-MELD), including lung cancer cases from a large catchment area in New York City. We identified cases through linkage to our institution’s cancer registry and a clinician-initiated, manually curated database. We linked all cases to the electronic health record and in-house tumor genomic testing results. We used natural language processing (NLP) to extract unstructured genomic testing results and detailed smoking history. We linked geocoded addresses to detailed area-level measures.Results:MCC-MELD contains 9,573 patients with lung cancer diagnosed from 1988 to 2024, of whom 20% were non-Hispanic Asian, 14% were non-Hispanic Black, and 8% were Hispanic. We identified 1,092 (11.4%) EGFR-mutant cancers, with NLP identifying 397 cases not identified by structured data. NLP showed high accuracy in ascertaining EGFR status (97%) and quantitative smoking history variables (90%–98%). Never smokers made up 16% of the cases in MCC-MELD.Conclusions:MCC-MELD is an NLP-enhanced database containing clinical information, genomic testing results, and linkages to area-level data for patients with lung cancer from a diverse urban setting.Impact:This resource can facilitate studies on lung cancer risk factors, treatment patterns, and outcomes by EGFR and other driver mutation status.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Method 2 from Design and Creation of a Racially Diverse Lung Cancer Registry with Detailed Genomic and Environmental Annotation
Supplementary Method 2. Final version of the quantitative smoking NLP prompt.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Method 2 from Design and Creation of a Racially Diverse Lung Cancer Registry with Detailed Genomic and Environmental Annotation
Supplementary Method 2. Final version of the quantitative smoking NLP prompt.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Design and Creation of a Racially Diverse Lung Cancer Registry with Detailed Genomic and Environmental Annotation
Supplementary Figure 3. Prevalence of EGFR mutation status by year.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Design and Creation of a Racially Diverse Lung Cancer Registry with Detailed Genomic and Environmental Annotation
Supplementary Figure 3. Prevalence of EGFR mutation status by year.